Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchAtovaquoneAtovaquone (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 
    
  
Atovaquone for COVID-19
1 study from 19 scientists
60 patients in 1 country
COVID-19 Atovaquone studies. May 2025. c19early.org
0 0.5 1 1.5+ All studies -39% Mortality -39% Hospitalization 16% RCTs -39% Late -39% Favorsatovaquone Favorscontrol
Sep 30
2022
Jain et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.1020123 Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial
39% higher mortality (p=1), 20% greater improvement (p=0.56), and 16% shorter hospitalization (p=0.07). RCT 60 hospitalized COVID-19 patients showing no significant difference in viral clearance with atovaquone. Patients were randomized 2:1 to receive atovaquone 1500mg BID or placebo for up to 10 days, with both groups receiving standard of..
Sep 9
2021
Pickard et al., PLOS Pathogens, doi:10.1371/journal.ppat.1009840 Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells
In Vitro studying identifying 35 compounds that inhibit SARS-CoV-2 in Vero cells and hepatocytes when treated prior to infection, and several compounds that slow replication when treated after infection: vitamin D, amodiaquine, atovaquone..
Jul 8
2021
Muthusamy et al., Journal of Virology & Antiviral Research Virtual Screening Reveals Potential Anti-Parasitic Drugs Inhibiting the Receptor Binding Domain of SARS-CoV-2 Spike protein
In Silico study identifying 32 anti-parisitic compounds effectively inhibiting the RBD of the SARS-CoV-2 spike protein, showing ivermectin and atovaquone among the top compounds.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit